Patients with previously untreated advanced squamous non-small-cell lung cancer lived significantly longer without their ...

Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.

A study by the University of Barcelona has discovered why the two main types of lung cancer—adenocarcinoma of the lung and ...

Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic options for LUSC remain limited, primarily due to the absence of well-defined, ...

Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic options for LUSC remain limited, primarily due to the absence of well-defined, ...

A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...

Ivonescimab plus chemotherapy helped patients with advanced squamous NSCLC live longer than tislelizumab plus chemotherapy. Patients with previously untreated advanced squamous non-small cell lung ...

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 ...